AN EXPERIMENTAL CYANOTIC CARDIOVASCULAR DISEASE MODEL

Cyanotic congenital heart disease.

The last 15 years have witnessed a very remarkable change in the attitude of the clinician towards cyanotic congenital heart disease. It is within the memory of many that it was the custom to make a simple diagnosis of congenital heart abnormality with cyanosis, and express the opinion that little or nothing could be done about it. Then there appeared the pioneer work of Abbott and others which...

Cyanotic Congenital Heart Disease

Probiotics improve insulin resistance status in an experimental model of Alzheimer’s disease

    Background: Nowadays, Alzheimer’s disease (AD) is considered as Type 3 diabetes in which insulin resistance is the common cause of both diseases. Disruption of insulin signaling cascade and insulin resistance can induce AD; and central insulin resistance causes systemic alterations in serum insulin, FBS levels, and lipid profile. Studies have shown that probiotics (Lact...

Effects of Adding Dexpanthenol to Prednisolone in an Experimental Model of Inflammatory Bowel Disease

Background & Objective: Inflammatory bowel diseases (IBDs) represent serious chronic auto-inflammatory conditions, affecting the alimentary tract. The beneficial effect of dexpanthenol has been observed on some inflammatory conditions. Here, the therapeutic potential of combined dexpanthenol and prednisolone in alleviating the symptoms of the animal model of IBD was investigated. Materials & M...

Adult cyanotic congenital heart disease.

The surgical treatment of cyanotic heart disease in the adult poses some technical difficulties in correcting severe anatomical deformities and compromised physiological states over a wide range of conditions. Various abnormalities and their surgical management have been reviewed. Forty-six patients over the age of 18 years have been operated with 10 operative deaths. Of the survivors, 63% have...